NCT00921167

A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas

A Phase II Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Anaplastic Astrocytoma or Recurrent Glioblastoma Multiforme

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Clinical Research Center for Solid Tumor, Korea · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy and safety of bevacizumab plus irinotecan for the patients with recurrent anaplastic astrocytoma or with recurrent glioblastoma multiforme

Conditions

• Glioblastoma
• Astrocytoma

Interventions

Type	Name	Description
DRUG	Bevacizumab/Irinotecan	Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs \[EIAEDs\] or 340mg/m2 for patients on EIAEDs) every 2 weeks

Timeline

• Start date: 2009-06-01
• Primary completion: 2012-06-01
• Completion: 2013-12-01
• First posted: 2009-06-16
• Last updated: 2013-12-04

Locations

1 site across 1 country: South Korea